| Mrs Kesha Renee Walton, DNP, APN, FNP-BC | |
|
2500 Brunswick Ave Ste 205, Lawrence, NJ 08648-4134 | |
| (732) 290-5480 | |
| (732) 716-3200 |
| Full Name | Mrs Kesha Renee Walton |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 2500 Brunswick Ave Ste 205, Lawrence, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164541124 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WE0003X | Registered Nurse - Emergency | 26NR11039900 (New Jersey) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 26NJ00470600 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Morristown Medical Center | Morristown, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Immediate Care Medical Walk-in Of Toms River | 8921228511 | 19 |
News Archive
Urologix®, Inc. (NASDAQ:ULGX), received a Staff Deficiency Letter from The Nasdaq Stock Market on September 17, 2009, stating that the Company's stockholders' equity at June 30, 2009 was less than the $10 million minimum required for continued listing on The Nasdaq Global Market under Marketplace Rule 5450(b)(1)(A).
Two contracts for advanced development of drugs to treat skin and lung injuries associated with acute radiation syndrome (ARS) were awarded this week by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). These contracts are the first by BARDA to address the skin and lung injuries that arise from acute exposure to high levels of ionizing radiation - the type of radiation that results from a nuclear blast.
In the next five years, 11 million African women and children could be saved by creating near-universal availability of key life-saving interventions, according to The Partnership for Maternal, Newborn & Child Health and the Countdown to 2015 Decade Report (2000-2010).
Fast development is often perceived as an advantage, as it enables better harmony with one's environment and readiness to cope with the challenges that it poses. However, research conducted at the University of Haifa, Israel, and University of California, Santa Cruz, and published in the scientific journal PLoS ONE, found that the acceleration of developmental rate incurs potentially lethal physiological costs for the developing individual.
› Verified 6 days ago
| Entity Name | Golding Granado Medical Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427243443 PECOS PAC ID: 6507953106 Enrollment ID: O20071112000132 |
News Archive
Urologix®, Inc. (NASDAQ:ULGX), received a Staff Deficiency Letter from The Nasdaq Stock Market on September 17, 2009, stating that the Company's stockholders' equity at June 30, 2009 was less than the $10 million minimum required for continued listing on The Nasdaq Global Market under Marketplace Rule 5450(b)(1)(A).
Two contracts for advanced development of drugs to treat skin and lung injuries associated with acute radiation syndrome (ARS) were awarded this week by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). These contracts are the first by BARDA to address the skin and lung injuries that arise from acute exposure to high levels of ionizing radiation - the type of radiation that results from a nuclear blast.
In the next five years, 11 million African women and children could be saved by creating near-universal availability of key life-saving interventions, according to The Partnership for Maternal, Newborn & Child Health and the Countdown to 2015 Decade Report (2000-2010).
Fast development is often perceived as an advantage, as it enables better harmony with one's environment and readiness to cope with the challenges that it poses. However, research conducted at the University of Haifa, Israel, and University of California, Santa Cruz, and published in the scientific journal PLoS ONE, found that the acceleration of developmental rate incurs potentially lethal physiological costs for the developing individual.
› Verified 6 days ago
| Entity Name | Immediate Care Medical Walk-in Of Toms River |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013337633 PECOS PAC ID: 8921228511 Enrollment ID: O20141002000774 |
News Archive
Urologix®, Inc. (NASDAQ:ULGX), received a Staff Deficiency Letter from The Nasdaq Stock Market on September 17, 2009, stating that the Company's stockholders' equity at June 30, 2009 was less than the $10 million minimum required for continued listing on The Nasdaq Global Market under Marketplace Rule 5450(b)(1)(A).
Two contracts for advanced development of drugs to treat skin and lung injuries associated with acute radiation syndrome (ARS) were awarded this week by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). These contracts are the first by BARDA to address the skin and lung injuries that arise from acute exposure to high levels of ionizing radiation - the type of radiation that results from a nuclear blast.
In the next five years, 11 million African women and children could be saved by creating near-universal availability of key life-saving interventions, according to The Partnership for Maternal, Newborn & Child Health and the Countdown to 2015 Decade Report (2000-2010).
Fast development is often perceived as an advantage, as it enables better harmony with one's environment and readiness to cope with the challenges that it poses. However, research conducted at the University of Haifa, Israel, and University of California, Santa Cruz, and published in the scientific journal PLoS ONE, found that the acceleration of developmental rate incurs potentially lethal physiological costs for the developing individual.
› Verified 6 days ago
| Entity Name | Urgent Care Physicians Of New Jersey Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447622402 PECOS PAC ID: 1658674585 Enrollment ID: O20160126002347 |
News Archive
Urologix®, Inc. (NASDAQ:ULGX), received a Staff Deficiency Letter from The Nasdaq Stock Market on September 17, 2009, stating that the Company's stockholders' equity at June 30, 2009 was less than the $10 million minimum required for continued listing on The Nasdaq Global Market under Marketplace Rule 5450(b)(1)(A).
Two contracts for advanced development of drugs to treat skin and lung injuries associated with acute radiation syndrome (ARS) were awarded this week by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). These contracts are the first by BARDA to address the skin and lung injuries that arise from acute exposure to high levels of ionizing radiation - the type of radiation that results from a nuclear blast.
In the next five years, 11 million African women and children could be saved by creating near-universal availability of key life-saving interventions, according to The Partnership for Maternal, Newborn & Child Health and the Countdown to 2015 Decade Report (2000-2010).
Fast development is often perceived as an advantage, as it enables better harmony with one's environment and readiness to cope with the challenges that it poses. However, research conducted at the University of Haifa, Israel, and University of California, Santa Cruz, and published in the scientific journal PLoS ONE, found that the acceleration of developmental rate incurs potentially lethal physiological costs for the developing individual.
› Verified 6 days ago
| Entity Name | Keys2health Wellness Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902472350 PECOS PAC ID: 7416357439 Enrollment ID: O20210614001351 |
News Archive
Urologix®, Inc. (NASDAQ:ULGX), received a Staff Deficiency Letter from The Nasdaq Stock Market on September 17, 2009, stating that the Company's stockholders' equity at June 30, 2009 was less than the $10 million minimum required for continued listing on The Nasdaq Global Market under Marketplace Rule 5450(b)(1)(A).
Two contracts for advanced development of drugs to treat skin and lung injuries associated with acute radiation syndrome (ARS) were awarded this week by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). These contracts are the first by BARDA to address the skin and lung injuries that arise from acute exposure to high levels of ionizing radiation - the type of radiation that results from a nuclear blast.
In the next five years, 11 million African women and children could be saved by creating near-universal availability of key life-saving interventions, according to The Partnership for Maternal, Newborn & Child Health and the Countdown to 2015 Decade Report (2000-2010).
Fast development is often perceived as an advantage, as it enables better harmony with one's environment and readiness to cope with the challenges that it poses. However, research conducted at the University of Haifa, Israel, and University of California, Santa Cruz, and published in the scientific journal PLoS ONE, found that the acceleration of developmental rate incurs potentially lethal physiological costs for the developing individual.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Kesha Renee Walton, DNP, APN, FNP-BC 2500 Brunswick Ave Ste 205, Lawrence, NJ 08648-4134 Ph: (732) 290-5480 | Mrs Kesha Renee Walton, DNP, APN, FNP-BC 2500 Brunswick Ave Ste 205, Lawrence, NJ 08648-4134 Ph: (732) 290-5480 |
News Archive
Urologix®, Inc. (NASDAQ:ULGX), received a Staff Deficiency Letter from The Nasdaq Stock Market on September 17, 2009, stating that the Company's stockholders' equity at June 30, 2009 was less than the $10 million minimum required for continued listing on The Nasdaq Global Market under Marketplace Rule 5450(b)(1)(A).
Two contracts for advanced development of drugs to treat skin and lung injuries associated with acute radiation syndrome (ARS) were awarded this week by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). These contracts are the first by BARDA to address the skin and lung injuries that arise from acute exposure to high levels of ionizing radiation - the type of radiation that results from a nuclear blast.
In the next five years, 11 million African women and children could be saved by creating near-universal availability of key life-saving interventions, according to The Partnership for Maternal, Newborn & Child Health and the Countdown to 2015 Decade Report (2000-2010).
Fast development is often perceived as an advantage, as it enables better harmony with one's environment and readiness to cope with the challenges that it poses. However, research conducted at the University of Haifa, Israel, and University of California, Santa Cruz, and published in the scientific journal PLoS ONE, found that the acceleration of developmental rate incurs potentially lethal physiological costs for the developing individual.
› Verified 6 days ago